Glenmark Pharmaceuticals’ arm launches Milnacipran Hydrochloride tablets

19 Mar 2026 Evaluate

Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. Glenmark’s Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg.

According to IQVIA sales data for the 12-month period ending January 2026, the Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market achieved annual sales of around $102.9 million.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

2181.05 82.75 (3.94%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×